This HTML5 document contains 94 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n21http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/AHFS/
n8http://linked.opendata.cz/resource/drugbank/company/
n10http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00107/identifier/kegg-drug/
n26http://linked.opendata.cz/resource/drugbank/dosage/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00107/identifier/drugbank/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00107/identifier/iuphar/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00107/identifier/guide-to-pharmacology/
n28http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB00107/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n25http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/medicinal-product/
n9http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n7http://linked.opendata.cz/ontology/drugbank/
n6http://www.drugs.com/cdi/
n22http://linked.opendata.cz/resource/drugbank/property/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00107/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00107/identifier/pharmgkb/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00107/identifier/kegg-compound/
n27http://linked.opendata.cz/resource/atc/
n16http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00107
rdf:type
n7:Drug
n7:description
Synthetic 9 residue cyclic peptide. The hormone is prepared synthetically to avoid possible contamination with vasopressin (ADH) and other small polypeptides with biologic activity.
n7:dosage
n26:271B45E1-363D-11E5-9242-09173F13E4C5 n26:271B45E2-363D-11E5-9242-09173F13E4C5 n26:271B45E3-363D-11E5-9242-09173F13E4C5
n7:generalReferences
# Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E: Oxytocin increases trust in humans. Nature. 2005 Jun 2;435(7042):673-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15931222 # Takayanagi Y, Yoshida M, Bielsky IF, Ross HE, Kawamata M, Onaka T, Yanagisawa T, Kimura T, Matzuk MM, Young LJ, Nishimori K: Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice. Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16096-101. Epub 2005 Oct 25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16249339 # Carmichael MS, Humbert R, Dixen J, Palmisano G, Greenleaf W, Davidson JM: Plasma oxytocin increases in the human sexual response. J Clin Endocrinol Metab. 1987 Jan;64(1):27-31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3782434 # Paquin J, Danalache BA, Jankowski M, McCann SM, Gutkowska J: Oxytocin induces differentiation of P19 embryonic stem cells to cardiomyocytes. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9550-5. Epub 2002 Jul 1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12093924 # Jankowski M, Danalache B, Wang D, Bhat P, Hajjar F, Marcinkiewicz M, Paquin J, McCann SM, Gutkowska J: Oxytocin in cardiac ontogeny. Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):13074-9. Epub 2004 Aug 17. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15316117 # Oxytocin. In DynaMed [database online]. EBSCO Information Services. http://search.ebscohost.com/login.aspx?direct=true&site=DynaMed&id=233015. Updated January 18, 2013. Accessed October 1, 2014. #Lexicomp. Oxytocin. N.p., 2014. Web. 11 Nov. 2014.
n7:group
approved
n7:halfLife
1-6 min, this is decreased in late pregnancy and during lactation.
n7:indication
Used for labor induction, augmentation of labor, postpartum abbreviation of third stage of labor, postpartum control of uterine bleeding, termination of pregnancy and for the evaluation of fetal respiratory capability. Oxytocin cannot be used for elective induction of labor, there must be a clear medical requirement.
n7:manufacturer
n8:271B45C1-363D-11E5-9242-09173F13E4C5 n8:271B45C2-363D-11E5-9242-09173F13E4C5 n8:271B45C3-363D-11E5-9242-09173F13E4C5 n8:271B45C4-363D-11E5-9242-09173F13E4C5 n8:271B45C5-363D-11E5-9242-09173F13E4C5 n8:271B45C6-363D-11E5-9242-09173F13E4C5
owl:sameAs
n25:DB00107 n28:DB00107
dcterms:title
Oxytocin
adms:identifier
n4:Oxytocin n11:2174 n12:2174 n13:DB00107 n14:0591-3553-69 n15:PA450760 n18:C00746 n20:D00089
n7:mechanismOfAction
Uterine motility depends on the formation of the contractile protein actomyosin under the influence of the Ca2+-dependent phosphorylating enzyme myosin light-chain kinase. Oxytocin promotes contractions by increasing the intracellular Ca2+, which in turn activates myosin's light chain kinase.. Oxytocin has specific receptors in the muscle lining of the uterus and the receptor concentration increases greatly during pregnancy, reaching a maximum in early labor at term.
n7:packager
n8:271B45B8-363D-11E5-9242-09173F13E4C5 n8:271B45B9-363D-11E5-9242-09173F13E4C5 n8:271B45B6-363D-11E5-9242-09173F13E4C5 n8:271B45B7-363D-11E5-9242-09173F13E4C5 n8:271B45B5-363D-11E5-9242-09173F13E4C5 n8:271B45C0-363D-11E5-9242-09173F13E4C5 n8:271B45BE-363D-11E5-9242-09173F13E4C5 n8:271B45BF-363D-11E5-9242-09173F13E4C5 n8:271B45BC-363D-11E5-9242-09173F13E4C5 n8:271B45BD-363D-11E5-9242-09173F13E4C5 n8:271B45BA-363D-11E5-9242-09173F13E4C5 n8:271B45BB-363D-11E5-9242-09173F13E4C5 n8:271B45B3-363D-11E5-9242-09173F13E4C5 n8:271B45B4-363D-11E5-9242-09173F13E4C5 n8:271B45B1-363D-11E5-9242-09173F13E4C5 n8:271B45B2-363D-11E5-9242-09173F13E4C5 n8:271B45AF-363D-11E5-9242-09173F13E4C5 n8:271B45B0-363D-11E5-9242-09173F13E4C5 n8:271B45AE-363D-11E5-9242-09173F13E4C5
n7:routeOfElimination
Biliary and renal (excreted unchanged in the urine)
n7:synonym
SID50111741 Pitocin Syntocinon SID29217903
n7:toxicity
Oxytocin can produce a severe water intoxication due to its antidiuretic effect. Prolonged IV infusions of more 40milliunits/min are usually the cause. Severe water intoxication with convulsions, coma, and death can occur. Some neonatal seizures have also been reported. Consider potential for water intoxication, particularly when administered by IV infusion and patient is receiving oral fluids. Uterine effects: High doses or hypersensitivity to oxytocin may cause uterine hypertonicity, spasm, tetanic contraction, or rupture of the uterus. There have also been reported allergic and anaphylactic reactions to oxytocin but they were rarely fatal.
n7:volumeOfDistribution
Distributes throughout the extracellular fluid and crosses the placenta. It is probable that it also distributes into milk in small amounts.
n16:hasAHFSCode
n17:76-00-00
n7:proteinBinding
30%
n7:synthesisReference
Kerstin Uvnas-Moberg, Thomas Lundeberg, "Use of substances having oxytocin activity for preparation of medicaments for wound healing." U.S. Patent US6262021, issued August, 1988.
n9:hasConcept
n10:M0015703
foaf:page
n6:oxytocin.html n21:oxytocin.htm
n7:Molecular-Formula
n22:271B45E7-363D-11E5-9242-09173F13E4C5
n7:Molecular-Weight
n22:271B45E6-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n27:H01BB02
n7:absorption
Uterine response after IV administration is immediate and subsides after 1 hour. Uterine contractions occur 3-5mins after IM administration and decreases within 2-3 hours. When 100-200milliunits is administered IV, contractions of the myoepithelial tissue surrounding the alveoli of the breasts occur within minutes and last for about 20 mins.
n7:affectedOrganism
Humans and other mammals
n7:casRegistryNumber
50-56-6
n7:category
n7:containedIn
n19:271B45C9-363D-11E5-9242-09173F13E4C5 n19:271B45CA-363D-11E5-9242-09173F13E4C5 n19:271B45C7-363D-11E5-9242-09173F13E4C5 n19:271B45C8-363D-11E5-9242-09173F13E4C5 n19:271B45E0-363D-11E5-9242-09173F13E4C5 n19:271B45DE-363D-11E5-9242-09173F13E4C5 n19:271B45DF-363D-11E5-9242-09173F13E4C5 n19:271B45DC-363D-11E5-9242-09173F13E4C5 n19:271B45DD-363D-11E5-9242-09173F13E4C5 n19:271B45DA-363D-11E5-9242-09173F13E4C5 n19:271B45DB-363D-11E5-9242-09173F13E4C5 n19:271B45D8-363D-11E5-9242-09173F13E4C5 n19:271B45D9-363D-11E5-9242-09173F13E4C5 n19:271B45D6-363D-11E5-9242-09173F13E4C5 n19:271B45D7-363D-11E5-9242-09173F13E4C5 n19:271B45D4-363D-11E5-9242-09173F13E4C5 n19:271B45D5-363D-11E5-9242-09173F13E4C5 n19:271B45D2-363D-11E5-9242-09173F13E4C5 n19:271B45D3-363D-11E5-9242-09173F13E4C5 n19:271B45D0-363D-11E5-9242-09173F13E4C5 n19:271B45D1-363D-11E5-9242-09173F13E4C5 n19:271B45CE-363D-11E5-9242-09173F13E4C5 n19:271B45CF-363D-11E5-9242-09173F13E4C5 n19:271B45CC-363D-11E5-9242-09173F13E4C5 n19:271B45CD-363D-11E5-9242-09173F13E4C5 n19:271B45CB-363D-11E5-9242-09173F13E4C5
n7:Hydrophobicity
n22:271B45E4-363D-11E5-9242-09173F13E4C5
n7:Isoelectric-Point
n22:271B45E5-363D-11E5-9242-09173F13E4C5